J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Sustainable change requires improved study design, market incentives, and patient involvement, write Kate Womersley and colleagues For too long, medical research has defaulted to male physiology, ...

The Cyprus issue, water scarcity issues and forest fires in the EU and developments in the Middle east will be among the topics discussed in the European Parliament’s (EP) plenary session held in ...